Page 211 - 2021_06-Haematologica-web

Brentuximab-R-CHP for CD30+ B-cell lymphomas
References
1. Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov. 2012;11:19.
2. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refrac- tory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
3. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
4. Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331-344.
5. Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lym- phoma (ECHELON-2): a global, double- blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229-240.
6. Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel sub- group of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715-2724.
7. Lu T-X, Liang J-H, Miao Y, et al. Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep. 2015;5:12168.
8. Slack GW, Steidl C, Sehn LH, Gascoyne RD. CD30 expression in de novo diffuse large B‐cell lymphoma: a population‐based study from British Columbia. Br J Haematol.
2014;167(5):608-617.
9. Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lym- phoma. Am J Clin Pathol. 1999;112(2):241- 247.
10.Barth TF, Leithauser F, Joos S, Bentz M, Moller P. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol. 2002;3(4):229-234.
11. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favor- able subgroup of diffuse large B cell lym- phoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862.
12.Mottok A, Steidl C. Biology of classical Hodgkin lymphoma: implications for prog- nosis and novel therapies. Blood. 2018;131 (15):1654-1665.
13. Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retro- spective study. Clin Lymphoma Myeloma. 2009;9(5):381-385.
14. Rieger M, Österborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treat- ed with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2010;22(3):664-670.
15.Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408-1416.
16. Gleeson M, Hawkes EA, Cunningham D, et al. Rituximab, cyclophosphamide, doxoru- bicin, vincristine and prednisolone (R- CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. Br J Haematol. 2016;175(4):668-672.
17.Bartlett NL, Wilson WH, Jung S-H, et al. Dose-adjusted EPOCH-R compared with R- CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol;2019; 37(21):1790-1799.
18. Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma com- pared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49(7):1329-1336.
19. Giulino-Roth L, O'Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treat- ed with dose-adjusted EPOCH-R. Br J Haematol. 2017;179(5):739-747.
20. Armand P, Rodig SJ, Melnichenko V, et al. Pembrolizumab in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL): data from the Keynote-013 and Keynote-170 studies. Blood. 2018;132(Suppl 1):228.
21.Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
22. Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130(3):267-270.
23. Moskowitz AJ, Santoro A, Gritti G, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: prelimi- nary results from the phase 2 CheckMate 436 trial. Blood. 2018;132(Suppl 1):1691.
24. Zinzani PL, Pellegrini C, Chiappella A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood. 2017;129(16):2328-2330.
25. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lym- phoma. J Clin Oncol. 2007;25(5):579-586.
26. Mottok A, Wright G, Rosenwald A, et al. Molecular classification of primary mediasti- nal large B-cell lymphoma using routinely
available tissue specimens. Blood. 2018;132
(22):2401-2405.
27. Schemper M, Smith TL. A note on quantify-
ing follow-up in studies of failure time.
Control Clin Trials. 1996;17(4):343-346.
28. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lym- phoma. N Engl J Med. 1993;329(14):987-
994.
29.Jacobsen ED, Sharman JP, Oki Y, et al.
Brentuximab vedotin demonstrates objec- tive responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394- 1402.
30. Shah NN, Szabo A, Huntington SF, et al. R- CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediasti- nal B-cell lymphoma: a multi-centre analy- sis. Br J Haematol. 2018;180(4):534-544.
31. Soumerai JD, Hellmann MD, Feng Y, Sohani AR, Toomey CE, Barnes JA. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma. 2014;55(3):538-543.
32. Martelli M, Ceriani L, Zucca E, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary medi- astinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study. J Clin Oncol. 2014;32(17):1769-1775.
33. Bartlett NL, Farber CM, Yasenchak CA, et al. Updated results of a phase II trial of brentux- imab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B- cell lymphoma (DLBCL). J Clin Oncol. 2015;33(15_suppl):8506.
34.Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated dif- fuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529-3537.
35. Lekovic D, Miljic P, Mihaljevic B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lym- phoma. Thromb Res. 2010;126(6): 477-480.
36. Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papu- losis. J Clin Oncol. 2015;33(32):3759-3765.
37. Kim YH, Prince HM, Whittaker S, et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. J Clin Oncol. 2017;35(15_suppl):7517.
38. Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81-e82.
haematologica | 2021; 106(6)
1713